Kailera Therapeutics Raises $600 Million
Investors have announced a significant private financing round for biotech company Kailera Therapeutics, pouring $600 million into the obesity drug startup.
The financing was led by Bain Capital's private equity group and included Royalty Pharma, the sovereign wealth fund in Qatar, and the asset manager of Canada's national pension plan. Several of Kailera's founding investors also contributed additional funds.
This deal highlights the ongoing interest in weight loss drugs, despite some clinical disappointments in recent years. Kailera's Series B round comes almost exactly one year after the startup launched with $400 million.
The investment also follows Pfizer's announcement to buy another privately held obesity drug developer, Metsera, for $4.9 billion.
No direct quotes available in the text.
Author's summary: Kailera Therapeutics raises $600 million in funding.